WHO ICTRP trial
Proof-of-concept, cross over, double blind, placebo-controlled study to assess…
EUCTR2007-005786-35-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2007-005786-35-DE |
|---|---|
| Public title | Proof-of-concept, cross over, double blind, placebo-controlled study to assess if Rupatadine 20 mg can improve critical stimulation time thresholds (CSTTs) in patients with acquired cold urticaria - ACURE |
| Scientific title | Proof-of-concept, cross over, double blind, placebo-controlled study to assess if Rupatadine 20 mg can improve critical stimulation time thresholds (CSTTs) in patients with acquired cold urticaria - ACURE |
| Primary sponsor | Uriach Pharma |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Germany;Spain |
| Conditions | Acquired Cold Urticaria MedDRA version: 9.1 Level: LLT Classification code 10009869 Term: Cold urticaria |
| Interventions | Trade Name: Rupafin Product Name: Rupafin Pharmaceutical Form: Tablet INN or Proposed INN: Rupatadine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route… |
| Registration date | Dec 14, 2007 |
| Target size | 20 |
| Secondary IDs | DC02RUP/IV/02 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: